Xceleron, JCL Bioassay Partner on Screening Technologies | GenomeWeb

NEW YORK (GenomeWeb News) – Xceleron announced today that it will collaborate with JCL Bioassay in offering drug developers access to their respective technologies for drug screening and development applications.

Xceleron said that the partnership will offer clinical design expertise and appropriate analytical platforms for early clinical investigation. It added that between the firms they have developed more than 100 analytical methods for Phase 0 and Phase 1 investigations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.